Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings

It has been less than a month since I initiated coverage on Regeneron (NASDAQ: REGN ), suggesting that the company represented a BUY based on promising growth from LIBTAYO and DUPIXENT and stabilizing sales in theBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and ...